Data was taken from 41 healthcare systems participating in the National Patient-Centered Clinical Research Network.
Five things to know:
1. This study found monoclonal antibody treatments have been used relatively less commonly in racial and ethnic minority groups, amplifying the increased risk for severe outcomes tied to COVID-19, including death.
2. Racial and ethnic differences were smaller for inpatient administration of remdesivir and dexamethasone, which may be attributed to ease of medication access, according to the CDC.
3. The treatment disparities findings are consistent with previous study findings
4. The study didn’t identify the underlying causes for the disparities.
5. The study findings highlight disparities as a priority for intervention and can guide strategies aimed at more equitable COVID-19 outcomes.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
